| Description | Mezagitamab (TAK-079), an IgG1λ anti-CD38 monoclonal antibody, functions by depleting tumor cells that express CD38 through both antibody and complement-dependent cytotoxicity. It shows potential for use in the treatment of relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) [1] [2] [3]. |
| molecular weight | N/A |
| CAS | 2227490-52-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |